A 38-year-old male patient with chronic myelocytic leukemia in the first chronic phase underwent bone marrow transplantation (BMT) from an HLA identical sibling. He developed chronic graft-versus-host disease and his condition gradually deteriorated. Fourteen months after BMT, acute progressive anemia, thrombocytopenia, reticulocytosis, increased serum lactic dehydrogenase and increased serum bilirubin were revealed following treatment with cyclosporine A (240 mg/day i.v.), prednisolone (60 mg/day i.v.) and azathioprine (lOO mg/day p.o.). Red blood cell fragmentations were also found microscopically. At that time, the serum cyclosporine A trough level was 1,300ng/ml by the polyclonal antibody RIA method. These symptoms were resolved by discontinuation of cyclosporine A and administrations of aspirin, cilostazol, and dipyridamole as anti-platelet agents. We consider this phenomenon to be micro angiopathic hemolytic anemia due to a serum high cyclosporine A level which resulted from the concomitant use of cyclosporine A with prednisolone.
Introduction
Cyclosporine A (CyA) and prednisolone (PSL) are often combined to treat graft-versus-host disease (GVHD) in bone marrow transplanted patients. Elevated plasma CyA concentration in patients receiving CyA and PSL combination therapy have been previously reported. We present a case of microangiopathic hemolytic anemia (MHA) during CyA and PSL therapy after bone marrow transplantation (BMT). In this case, a high serum CyA concentration due to the combined use with PSL might be involved in this disease.
Case Report
A 38-year-old male with Philadelphia chromosome (Phl)-positive chronic myelocytic leukemia (CML) in the first chronic phase was transplanted with HLA identical, mixed lymphocyte culture (MLC)-negative sibling's marrow on October 30, 1987. Prophylaxis of GVHD was performed by CyA 200mg/day i.v. in 2 divided doses every day and methotrexate (MTX) 10mg/m2 i.v. on day 1, and 6mg/m2i.v. on days 3, 7, and ll. His grade 1 cutaneous GVHD was resolved without any treatment except for the same dosage of CyA adminis tration. Three months after BMT he discontinued oral CyA at his own discretion. Soon thereafter, chronic systemic GVHD, with associated sclerosis of the skin, desquamation and hepatic dysfunction appeared. He was started on an oral regimen of CyA 200mg/day, PSL 30mg/day and azathioprine lOOmg/day. Since chronic GVHD continued to progress slowly, he was admitted to the hospital in January 1989, 14 months after BMT. In-patient treatment was started immediately with CyA 240mg/day i.v. in 2 divided doses, PSL 60mg/day given by continuous infusion and azathioprine lOO mg/day p.o. One week later, serum bilirubin, LDH and creatinine were elevated, anemia rapidly worsened, platelet count decreased and reticulocyte count markedly increased ( dose to 120mg/day i.v. and further to 60mg/day i.v., the trough level was found to be 370 and 180 ng/ml, respect ively. Unfortunately, since serum bilirubin remained high, CyA was discontinued after being given for 22 days. Cessation of CyA administration and the use of aspirin, cilostazol and dipvridamole as anti-platelet agents for a subsequent period of about 2 months resulted in the return to normal of bilirubin, LDH, serum creatinine level and reticulocyte count, with concurrent disappear ance of fragmented red blood cells. However, the GFR did not return to normal, thus precluding renal biopsy. Azathioprine was also discontinued after ll days, use. PSL alone was used for the control of chronic GVHD, with gradual symptom improvement (Fig. 2) . The patients' condition is now improving, and PSL has been tapered down to a maintenance dose. occurrence of MHA, we assumed that the direct influence of high-dose CyA might have played a primary role in the causation of MHA in the present case. Chronic GVHD and the use of azathioprine both of which impair liver metabolism might be implicated as the cause of the high serum CyA level in this patient. As far as his biochemical data are concerned, however, his liver dysfunction was minimal. Therefore, azathioprine and chronic GVHD might be marginal in relation to the elevated serum CyA levels, and PSL was most likely significant. In this case, the combined use of CyA and PSL was considered the probable cause of the increased serum CyA concentrations and the subsequent devel opment of MHA. Reported evidence indicates that the combined use of CyA and PSL yields elevated plasma levels of CyA (5). According to Ost, PSL and CyA are both metabolized in the liver by cytochrome P-450 and, accordingly, the concomitant use of these two compounds might competi tively inhibit their metabolism (6) . In fact, he reported that the concomitant use of the two drugs causes the metabolism of PSL to be delayed. Gratifying results of alternate therapy with CyA and PSL in the management of chronic GVHD reported recently (7) may be attrib utable to the elevated blood levels of the two drugs. High plasma concentrations of CyA and the occurrence of MHA were associated with overdosage of CyA (1, (8) (9) (10) or combined use of steroids in massive doses in most instances (5, ll, 12) , while similar phenomena occurring from a combination of CyA and PSL used in standard doses are exceedingly rare. Blood levels of CyA, on most occasions, are determined by the RIA method and measurements thus obtained are said to correlate with those by high performance liquid chromato graphy (HPLC) (13) . With regard to the blood levels of CyA as assayed by HPLC, there is a report that whole blood CyA clearance is more rapid when CyA is used in conjunction with a large dose of methylprednisolone than with a maintenance dose of PSL (14) . In reported MHA cases, however, plasma levels of CyA were not consistently high (12) and, moreover, these complications occurred even in patients not receiving CyA (2).
Discussion
The reason why MHA did not lead to uremia and give rise to relatively less severe renal damage in the present case is unclear. MHA might involve the capillaries mainly in organs other than the kidney. The fact that the renal disorder was CyA-associated and not MHA-associated glomerulopathy is also a likely possibility. This particular case indicates that transplant patients receiving CyA and PSL should have frequent measure ment of blood CyA levels, even if the PSL administration dosage is not high.
